Is MCOV-B.ST overvalued or undervalued?

MCOV-B.ST currently has a P/E ratio of 42.02. Relative to the sector average of 36.50, this suggests the stock may be overvalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Medicover AB (publ) stock?

Medicover AB (publ) trades on STO. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of MCOV-B.ST?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying MCOV-B.ST protect my money against local inflation?

Many investors in Latin America buy international stocks like MCOV-B.ST to protect their purchasing power. Because MCOV-B.ST is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy MCOV-B.ST shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is MCOV-B.ST a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well MCOV-B.ST diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksMCOV-B.ST

Medicover AB (publ)

kr 263.50+kr 3.50+1.35%

STO / SEK

Market cap

kr 39.8B

P/E

42.0

EPS (TTM)

kr 0.66

Dividend yield

0.83%

Beta

1.50

1Y return

+0.19%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$1.6B2021

$1.6B2022

$1.9B2023

$2.2B2024

$2.8B2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity2.72High
Current ratio0.55
Cash ratio0.09
Net margin3.4%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

MCOV-B.ST42.0
Healthcare sector median36.5
S&P 50022.0

Trades about 15% above its sector, the market expects faster growth.

Ratios

PEG0.45
Price to book6.65
EPS (TTM)kr 0.66
Payout ratio3,595%
FCF yield6.07%

Range & risk

kr 179.40kr 267.00

Trading in the upper third of its 52-week band

Beta1.50

Profile

What Medicover AB (publ) actually does

Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It is structured into two main divisions: Healthcare Services and Diagnostic Services. Through its diagnostic division, Medicover performs a comprehensive array of specialized tests, which include analyses for allergy and autoimmune conditions; bacteriology and parasitology; biochemistry and immunochemistry; blood group diagnostics and transfusion medicine; tumour markers; clinical chemistry; cellular analyses like cytology, haematology, and histopathology; human genetics; hygiene; general immunology; infectious diseases; microbiology; molecular biology; and pharmacology/toxicology. Medicover maintains a substantial operational footprint, encompassing 97 clinical laboratories, 733 blood-drawing points, and 26 clinics dedicated to diagnostic services across 10 countries. Its healthcare segment further comprises 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. The company caters to a broad customer base, serving corporate entities, private individuals, direct patients, and public sector payers.

CEO

John Paul Stubbington

Employees

49,000

Headquarters

Stockholm, AB

Founded

2017-05-23

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save MCOV-B.ST and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

MCOV-B.ST has a beta of 1.50, which indicates how sensitive it has historically been to movements in its broader market. A beta above 1 suggests higher relative volatility than the market. Beta is based on historical data and does not predict future performance.

Medicover AB (publ)